Qualified Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Enterprise AI for health systems; raised $125M Series B (NEA + Anthropic fund, March 2026); 500K+ users; AI agents covering ~7% of US hospital revenue; integrates with existing EHR systems
About
Qualified Health is an enterprise AI company building intelligent systems for large health systems and hospital networks. Founded to address the complexity of clinical and operational decision-making in healthcare, the company develops AI agents that assist clinicians, administrators, and care teams with data-intensive workflows. Its platform is designed to integrate with existing electronic health record systems and enterprise infrastructure, enabling health systems to deploy AI without replacing legacy technology.\n\nThe company targets enterprise health systems — specifically the largest hospital networks in the United States — with AI tools that span clinical decision support, administrative automation, and patient engagement. Qualified Health emphasizes safety, compliance, and interpretability in its models, which is critical for adoption in regulated healthcare settings. The platform is built to handle the scale and data sensitivity requirements of organizations managing hundreds of thousands of patients.\n\nQualified Health raised a $125M Series B led by NEA and backed by the Anthropic fund, signaling strong confidence from both traditional healthcare investors and AI-native institutional backers. The company has grown to 500,000+ users and its platform now touches approximately 7% of total US hospital revenue — a remarkable reach for a relatively young company. As of early 2026, Qualified Health is one of the best-capitalized enterprise health AI startups in the market.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.